Clinical Trials Sponsored by American Regent, Inc.

Total 1223 results

Bausch Health Americas, Inc.

Terminated

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis (AMAGINE-2)

Moderate to Severe Plaque Psoriasis

United States, Austria, France, Poland, Australia, Czechia, Canada, Hungary, Portugal, Spain, Netherlands
Bausch Health Americas, Inc.

Terminated

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3)

Plaque Psoriasis

United States, Belgium, Italy, Hungary, Poland, Australia, France, Greece, Russian Federation, Latvia, Canada
Bausch Health Americas, Inc.

Completed

12-Week Study of Plecanatide for CIC (The CIC3 Study)

Chronic Idiopathic Constipation

United States, Canada
Bausch Health Americas, Inc.

Completed

(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

Ulcerative Colitis

United States, Canada, India, Mexico
Bausch Health Americas, Inc.

Completed

Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers

Pharmacokinetic
Bausch Health Americas, Inc.

Terminated

Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201

Hepatitis B, Chronic
Bausch Health Americas, Inc.

Completed

Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult Subjects

Healthy Adult Subjects

United States
Bausch Health Americas, Inc.

Completed

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS) (TARGET 1)

Non-Constipation Irritable Bowel Syndrome

United States, Canada
Bausch Health Americas, Inc.

Completed

Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan

Healthy Adults

United States
Bausch Health Americas, Inc.

Completed

Open-Label Treatment Extension of Protocol MNTX 301

Terminal Illness

United States
Bausch Health Americas, Inc.

Completed

Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cruris

Tinea Pedis | Tinea Cruris

Dominican Republic, Honduras
Bausch Health Americas, Inc.

Completed

Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function

Renal Impairment

United States
Bausch Health Americas, Inc.

Completed

Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative Ileus

Postoperative Ileus

United States
Bausch Health Americas, Inc.

Completed

Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX

Healthy Adult Subjects

United States
Bausch Health Americas, Inc.

Completed

Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose

Healthy Subjects

United States
Bausch Health Americas, Inc.

Completed

Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.

Diarrhea

United States
Bausch Health Americas, Inc.

Completed

Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus

Post Operative Bowel Dysfunction

Germany, Italy, United States, Hungary, Korea, Republic of, South Africa, Poland, Australia, Romania, Former Serbia and Montenegro
Bausch Health Americas, Inc.

Completed

Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI) (SoFI)

Fecal Incontinence

United States
Bausch Health Americas, Inc.

Completed

Diarrhea Predominant Irritable Bowel Syndrome in Females

Irritable Bowel Syndrome

United States
Bausch Health Americas, Inc.

Completed

New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis

Ulcerative Colitis

United States
Bausch Health Americas, Inc.

Completed

Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain

Constipation

United States
Bausch Health Americas, Inc.

Completed

Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill

Upper Gastrointestinal Bleeding

United States
Bausch Health Americas, Inc.

Completed

Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy

Chronic Hepatitis C
Bausch Health Americas, Inc.

Completed

A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®

Chronic Idiopathic Constipation

United States
Bausch Health Americas, Inc.

Completed

Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis

Liver Cirrhosis

United States, Russian Federation
Bausch Health Americas, Inc.

Completed

A Single-Center, Open-Label, Exploratory Study of the Volumizing Effect of SCULPTRA Measured by Three Dimensional Digital Surface Imaging

Mid Facial Contour Deficiencies

United Kingdom
Bausch Health Americas, Inc.

Completed

DL6049 vs CosmoPlast in the Treatment of Nasolabial Fold Wrinkles

Nasolabial Fold Wrinkles

United States
Bausch Health Americas, Inc.

Completed

DL6049 Versus Cosmoplast in the Treatment of Nasolabial Fold Wrinkles, Long Term Follow-up

Nasolabial Fold Wrinkles

United States
Bausch Health Americas, Inc.

Completed

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

Hepatic Encephalopathy | Cirrhosis

United States
Bausch Health Americas, Inc.

Completed

Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

Ulcerative Colitis

United States, Bulgaria, Canada, Czechia, Estonia, Hungary, Latvia, Lithuania, Poland, Russian Federation, Ukraine
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

Proctitis | Proctosigmoiditis

United States
Bausch Health Americas, Inc.

Completed

12-Week Study of Plecanatide for CIC (The National CIC3 Study) (CIC)

Chronic Idiopathic Constipation

United States
Bausch Health Americas, Inc.

Completed

Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827

Psoriasis
Bausch Health Americas, Inc.

Completed

Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream

Acne

United States
Bausch Health Americas, Inc.

Completed

Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne Vulgaris

Acne

United States
Bausch Health Americas, Inc.

Terminated

Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis (AMVISION-1)

Psoriatic Arthritis

United States, Italy, Spain, Hungary, Belgium, Mexico, Poland, Switzerland, United Kingdom, Russian Federation, Canada, Greece, France, Bulgaria, Slovakia, Estonia, Czech Republic
Bausch Health Americas, Inc.

Completed

Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability

Eye Pain

United States
Bausch Health Americas, Inc.

Completed

Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)

Chronic Hepatitis C

United States
Bausch Health Americas, Inc.

Completed

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive

Chronic Hepatitis C
Bausch Health Americas, Inc.

Completed

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive (VISER2)

Chronic Hepatitis C

United States, Spain, Italy, Australia, Canada, Poland, Puerto Rico, Russian Federation, Argentina, France, Israel, United Kingdom
Bausch Health Americas, Inc.

Completed

A Study Comparing the Effectiveness and Safety of Extended-release Tramadol Versus Placebo in the Treatment of Chronic Low Back Pain

Chronic Pain
Bausch Health Americas, Inc.

Completed

A One-year, Open-label Study to Assess the Safety and Effectiveness of Extended Release Tramadol HCl in the Treatment of Chronic, Non-malignant Pain.

Chronic Pain

United States
Bausch Health Americas, Inc.

Completed

Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face.

Acne Vulgaris

United States
Bausch Health Americas, Inc.

Completed

A Study of Acne Treatment in Children Ages 9 to 11

Acne Vulgaris

United States
Sumitomo Pharma America, Inc.

Recruiting

A Study of Oral TP-3654 in Patients With Myelofibrosis

Myelofibrosis

United States, Belgium, France, Japan, Australia, Italy, United Kingdom
Sumitomo Pharma America, Inc.

Completed

A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

Schizophrenia

United States
Merz North America, Inc.

Active, not recruiting

Prospective Study to Assess Tissue Responses After Injection With Biostimulatory Products

Injection Site Reaction

Spain
Sumitomo Pharma America, Inc.

Terminated

A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

Fallopian Tube Cancer | Primary Peritoneal Cancer | Urothelial Carcinoma | Renal Cell Carcinoma (RCC) | Platinum-resistant Ovarian Cancer (PROC) | Serous Epithelial Ovarian Cancer

United States, Canada
Sumitomo Pharma America, Inc.

Completed

A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia

Schizophrenia

United States
Sumitomo Pharma America, Inc.

Enrolling by invitation

An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication

Schizophrenia

United States

3

Subscribe